Top 3 Health Care Stocks Which Could Rescue Your Portfolio In Q3
Healthcare stocks UTHR, COLL and AHG show oversold RSI levels near or below 30, potentially offering undervalued buying opportunities.
Stocks · News reference
Collegium Pharmaceutical Lowers FY2026 Sales Guidance from $865.000M-$895.000M to $825.000M-$855.000M vs $872.278M Est
Collegium Pharmaceutical (NASDAQ:COLL) lowers FY2026 sales outlook from $865.000 million-$895.000 million to $825.000 million-$855.000 million vs $872.278 million estimate.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $48
Barclays analyst Glen Santangelo maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Overweight and lowers the price target from $56 to $48.
Collegium Pharma shares are trading higher after the company announced a $50 million accelerated share repurchase program.
Collegium Pharmaceutical Announces $50M Accelerated Share Repurchase Agreement With Jefferies, With Initial Delivery Of 1,556,420 Shares; $100M To Remain Under Program